SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Company sold 29,913 Class D Common Shares for $825,000 on June 1, 2026, pursuant to a continuous private placement offering of up to $2.165 billion in common shares under Section 4(a)(2) and Regulation D Rule 506(c). This is a classic unregistered equity issuance that creates dilution to existing shareholders and is material to investors assessing the Company's capital structure and future equity value.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting held on June 4, 2026, including tabulated votes for the election of four directors (David Ayoub, William Barclay, James Dowd, and John Sharkey) and ratification of Bonadio & Company, LLP as independent auditor. The detailed vote tallies and Item 5.07 designation are unmistakable indicators of shareholder voting outcomes.
View raw filing on EDGAR →This Item 5.07 discloses the certified results of shareholder votes at the June 3, 2026 annual meeting, including the election of two Class II directors (Timothy M. Lamothe and Isolde G. O'Hanlon) and ratification of Grant Thornton LLP as independent auditor. The filing presents vote tallies for each proposal, which is the core content of shareholder_vote_results disclosures.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Heritage Global Inc.'s 2026 Annual Meeting of Shareholders held on June 3, 2026. The filing reports voting outcomes for two proposals: (1) election of Michael Hexner and William Burnham as Class II directors, with specific vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of UHY LLP as independent auditor for fiscal year 2026, with detailed vote counts. This directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders (Item 5.07).
View raw filing on EDGAR →The filing discloses the appointment of Raymond Cole as Interim Chief Financial Officer on June 1, 2026. While the Item 5.02 header encompasses both departures and appointments, the principal disclosed action is a person taking a role (appointment), not leaving. The disclosure includes Cole's background, compensation ($32,500/month), and confirms no related-party conflicts, which is standard for executive appointments and material to investors assessing management quality.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final voting results from CarGurus' June 3, 2026 annual meeting of stockholders, covering three proposals: election of Class III directors (Manik Gupta and Langley Steinert), ratification of Ernst & Young LLP as independent auditors, and a non-binding advisory vote on named executive officer compensation. The disclosure of shareholder vote outcomes is the core material event required under Item 5.07.
View raw filing on EDGAR →Stockholders voted on five proposals at the June 3, 2026 Annual Meeting: election of Michael Heffernan as a Class I director, ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, approval of the Amended and Restated 2019 Stock Incentive Plan increasing available shares by 8,000,000, and approval of an amendment to increase authorized common shares from 200 million to 400 million. All proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from OneSpaWorld's June 3, 2026 Annual Meeting of Shareholders. The filing reports voting outcomes for four proposals: election of seven directors, advisory vote on named executive officer compensation, approval of an amended equity incentive plan, and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (For/Against/Abstain/Broker non-votes) for each proposal are the hallmark of Item 5.07 disclosures and constitute material information about shareholder governance actions.
View raw filing on EDGAR →Kura Oncology held its Annual Meeting of Stockholders on June 4, 2026, with shareholders voting on six proposals including director elections, auditor ratification, Say-on-Pay advisory vote, Say-on-Pay frequency, and approval of amendments to the 2014 Equity Incentive Plan and ESPP.
View raw filing on EDGAR →Fulcrum's board approved a comprehensive restructuring plan involving an 85% workforce reduction (from 57 to 9 employees) and $4.2 million in charges, triggered by the discontinuation of pociredir development for sickle cell disease. This represents a significant strategic pivot with material implications for the company's operational scale and capital preservation.
View raw filing on EDGAR →Fulcrum initiated a comprehensive strategic review and engaged Leerink Partners LLC as financial advisor to evaluate potential strategic alternatives, including merger, acquisition, business combination, sale or licensing of assets, or other strategic transactions. No transaction has been approved or agreed upon at this time.
View raw filing on EDGAR →Minerva Neurosciences held its 2026 Annual Meeting of Stockholders on June 3, 2026, with shareholders voting on six proposals including director elections, charter amendments, advisory compensation votes, and auditor ratification. All proposals were approved by stockholders.
View raw filing on EDGAR →The disclosure announces a 1-for-10 reverse stock split of Offerpad's Class A common stock, approved by stockholders on June 3, 2026 and effective June 8, 2026. While reverse stock splits are material corporate actions affecting share structure, trading symbol, and CUSIP, they do not fit neatly into the more specific event categories (not M&A, not an impairment, not a covenant breach, not a delisting notice per se). This is classified as other_material because it is a significant structural change that would affect a reasonable investor's assessment of the company's capitalization and trading mechanics, but lacks a dedicated taxonomy category.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Funko's Annual Meeting of Stockholders held on June 3, 2026. The filing reports the outcomes of three proposals: election of three Class III directors (Diane Irvine, Jesse Jacobs, and Sarah Kirshbaum Levy), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. All three items passed. This is a quintessential Item 5.07 disclosure and is material to investors as it documents the composition of the board and auditor ratification.
View raw filing on EDGAR →Brad W. Hansman was appointed effective June 1, 2026, to the position of Executive Vice President, Operations, a principal operating officer role. The disclosure includes his background, compensation ($492,250 base salary plus incentive eligibility), and confirms no conflicts of interest. This is a material executive appointment to a senior leadership position responsible for operations.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Kalaris Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting results for four matters: election of three Class III directors (Napoleone Ferrara, David Hallal, and Leone Patterson), advisory approval of named executive officer compensation, recommendation on frequency of future advisory compensation votes (approved for annual frequency), and ratification of Deloitte & Touche LLP as independent auditor. All votes passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Amylyx Pharmaceuticals' Annual Meeting of Stockholders held on June 4, 2026. The filing reports the final vote tallies for three proposals: election of Class II directors (George Mclean Milne Jr., Ph.D. and Paul Fonteyne), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. This is a textbook Item 5.07 shareholder vote results disclosure, material to investors as it reflects stockholder decisions on governance and audit matters.
View raw filing on EDGAR →This is a classic Item 3.02 disclosure of an unregistered sale of equity securities. The Company sold 2,845,626 Class S-2 shares for approximately $41.0 million to accredited investors under Section 4(a)(2) and Regulation D exemptions. The sale is material as it represents a significant capital raise and dilution to existing shareholders, and the unregistered nature signals a private placement typical of dilutive issuances at smaller or mid-cap REITs.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Stoke Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026, including voting outcomes for three proposals: election of three Class I directors (G. Clare Kahn, Adrian Krainer, and Julie Anne Smith), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (Shares For, Against, Withheld, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures under Item 5.07.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Tenax Therapeutics' 2026 annual meeting of stockholders held on June 2, 2026. The filing presents voting results for two proposals: (1) election of seven directors to one-year terms, with vote tallies for each nominee (For/Withheld/Broker Non-Votes), and (2) ratification of Cherry Bekaert LLP as independent auditor. The disclosure is material as it documents the outcome of shareholder governance actions and confirms the composition of the board and auditor selection.
View raw filing on EDGAR →The filing discloses Planet Labs PBC's issuance of a press release announcing financial results for the first fiscal quarter ended April 30, 2026, with a conference call scheduled to discuss the results. This is a classic earnings release disclosure under Item 2.02, with the press release attached as Exhibit 99.1. Quarterly financial results are material to investors' assessment of the registrant's operational performance.
View raw filing on EDGAR →CV Sciences held its 2026 Annual Meeting on June 2, 2026, with shareholders voting on three proposals: election of three directors (passed), authorization of a reverse stock split (failed), and ratification of Haskell & White LLP as independent auditor (passed). The filing reports final voting tallies including vote counts, percentages, and broker non-votes.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 annual meeting held on June 2, 2026, covering three matters: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation. The filing presents vote tallies (for, against, withheld, abstain, broker non-votes) for each matter, which is the standard format for Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →OnKure held its Annual Meeting of Stockholders on June 3, 2026, with shareholders voting on three proposals: election of Class II directors (Carruthers, Jansen, Mathers), ratification of KPMG LLP as independent auditor, and approval of the Amended and Restated 2024 Equity Incentive Plan. Vote results for all three proposals are disclosed with detailed tallies.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of MasterBrand's Annual Meeting of Shareholders held on June 4, 2026. The filing presents voting results for three proposals: election of three directors (Ann Fritz Hackett, R. David Banyard, Jr., and Philip Fracassa), advisory approval of 2025 NEO compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three proposals passed with substantial majorities. Shareholder vote results are material to investors as they reflect governance outcomes and stakeholder approval of key corporate matters.
View raw filing on EDGAR →AN2 Therapeutics announced positive clinical trial results for AN2-502998, an oral CPSF3 inhibitor for chronic Chagas disease, including 100% parasite elimination in a 28-day NHP study with no adverse events and Phase 1 FIH data demonstrating good tolerability and human exposures meeting efficacy thresholds. For a clinical-stage biopharmaceutical company, these results are material to investors' assessment of pipeline value and development progress.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Royalty Pharma's 2026 Annual General Meeting held on June 4, 2026. The filing presents detailed vote tabulations for all 10 proposals submitted to shareholders, including director elections, executive compensation approval, auditor ratification, and share authorization matters. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly reports the inspector of election's certified vote counts for each proposal.
View raw filing on EDGAR →Prudential Financial closed a $750 million issuance of junior subordinated notes on June 4, 2026. While this is a material capital-raising event affecting the company's debt structure and financial position, it does not fit cleanly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or earnings release). The disclosure is material to investors as it represents a significant financing transaction, but the taxonomy lacks a dedicated "debt issuance" category, making "other_material" the most appropriate classification.
View raw filing on EDGAR →Sarepta held its Annual Meeting of Stockholders on June 4, 2026, with stockholders voting on five proposals: election of five Class I directors (Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly), advisory approval of named executive officer compensation, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and ratification of KPMG as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →Kathryn Gregory's resignation from the Board of Directors effective June 1, 2026 is a clear executive departure. The filing explicitly states her resignation and the effective date, with a standard disclaimer that it was not due to disagreement. Board departures are material events affecting the composition of the registrant's governance and oversight structure.
View raw filing on EDGAR →Kaiser Aluminum held its 2026 Annual Meeting of Stockholders, with results including election of three Class I directors (Hoffman, Minor, Wilcox), advisory approval of named executive officer compensation (98.68% for), ratification of Deloitte & Touche LLP as independent auditor (98.20% for), and approval of the Amended 2021 Equity and Incentive Compensation Plan increasing available shares by 395,000 (94.43% for).
View raw filing on EDGAR →The filing discloses the appointment of Shelley Bausch as a Class II director effective July 1, 2026, and her appointment to the Audit Committee. While the disclosure also includes compensatory arrangements (annual cash retainer of $100,000, equity grants of $125,000, and committee fees), the principal action is the director appointment itself. The Board increased the board size from 7 to 8 directors specifically to accommodate this appointment, making it a material governance event.
View raw filing on EDGAR →Michael L. Perkins, Senior Executive Vice President and Chief Risk Officer, is retiring effective June 30, 2026. While the filing also discloses a consulting arrangement with compensation terms, the principal disclosed action is the departure of a named executive from his officer role. The retirement of a C-suite executive responsible for risk oversight is material to investors' assessment of the company's governance and risk management continuity.
View raw filing on EDGAR →CRISPR Therapeutics held its Annual Meeting on June 4, 2026, and disclosed the final voting results for 13 proposals, including approval of financial statements, board re-elections, compensation approvals, capital increases, and auditor re-elections, with detailed tabulation of votes cast for each proposal.
View raw filing on EDGAR →Shareholders approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan on June 4, 2026, establishing a framework for future equity-based compensation awards including stock options, restricted stock units, performance shares, and other awards to directors and officers.
View raw filing on EDGAR →Applied Aerospace & Defense completed an initial public offering on June 4, 2026, selling 32.5 million shares at $20.00 per share pursuant to a definitive underwriting agreement. The IPO involved registration rights agreements and stockholders agreements that materially affected the company's capital structure and ownership.
View raw filing on EDGAR →In connection with the IPO, the company adopted compensatory arrangements for directors and executive officers, including indemnification agreements, the 2026 Omnibus Incentive Plan, and the 2026 Employee Stock Purchase Plan.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from LifeStance Health Group's June 2, 2026 annual meeting. The filing reports voting outcomes for three proposals: election of directors (Proposal 1), ratification of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory vote on named executive officer compensation (Proposal 3), with detailed vote tallies for each. This is a material disclosure as it documents stockholder approval of key governance matters including board composition and auditor selection.
View raw filing on EDGAR →Mr. Nicholas Maestas resigned as Chief Financial Officer and Principal Financial Officer effective June 5, 2026, affecting the registrant's financial leadership.
View raw filing on EDGAR →Tempest Therapeutics appointed Drake Richey and John Yee, MD, MPH to the Board of Directors, affecting the company's governance and strategic direction.
View raw filing on EDGAR →Alphabet entered into an at-the-market (ATM) equity distribution agreement on June 1, 2026, authorizing the sale of up to $40 billion of Class A and Class C shares through Goldman Sachs, J.P. Morgan, and Morgan Stanley.
View raw filing on EDGAR →Alphabet disclosed two material equity issuances: a registered public offering of approximately 25.5 million shares each of Class A and Class C stock at ~$355 and ~$352 per share, and a private placement of 14.2 million Class A and 14.4 million Class C shares to a Berkshire Hathaway affiliate for $10 billion gross proceeds under Section 4(a)(2) exemption.
View raw filing on EDGAR →IQVIA announced a €950 million senior notes offering due 2033 at 4.625% per annum, with expected closing on June 11, 2026. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy categories (not M&A, not a dilutive equity issuance, not a covenant breach or going-concern disclosure). This is a significant debt issuance that would affect investor assessment of the registrant's financial position and leverage.
View raw filing on EDGAR →Jade Biosciences entered into an underwriting agreement on June 3, 2026 to issue and sell 10,000,000 shares of common stock at $15.00 per share, with expected net proceeds of approximately $140.3 million (or $161.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected proceeds is characteristic of a dilutive equity issuance material to investors.
View raw filing on EDGAR →This is a Form 8-K Item 5.07 disclosure of shareholder meeting results. The filing reports the final voting outcomes for three proposals at the June 4, 2026 annual meeting: election of two Class II directors (Malte Peters, M.D. and Mace Rothenberg, M.D.), ratification of PricewaterhouseCoopers, LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote tallies, quorum confirmation (90.96% attendance), and context regarding a prior director resignation. This is a material event as it reflects stockholder decisions on board composition and corporate governance matters.
View raw filing on EDGAR →This Item 5.07 disclosure presents the tabulated results of stockholder votes at Arteris's June 2, 2026 Annual Meeting of Stockholders on two proposals: election of three Class II directors and ratification of Deloitte & Touche, LLP as the independent auditor for fiscal 2026. The filing provides vote counts (For, Against/Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Kodiak Sciences' June 2, 2026 Annual Meeting of Stockholders. The filing presents voting outcomes for three proposals: election of Class II directors (Bancroft, Dahiyat, and Yang), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and executive accountability.
View raw filing on EDGAR →Aeva Technologies entered into an Underwriting Agreement on June 3, 2026, to conduct a registered public offering of approximately 4.5 million shares of common stock at $22.25 per share, with an additional option for 674,157 shares, raising approximately $94.4 million (or $108.7 million with full option exercise). This material equity issuance will dilute existing shareholders.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from LeMaitre Vascular's June 2, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on three proposals: election of two Class II directors (David B. Roberts and John A. Roush), advisory approval of executive compensation, and ratification of Grant Thornton LLP as independent auditor. All three proposals passed by majority vote. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →Gulf Resources disclosed non-reliance on previously issued financial statements under Item 4.02, stating it will amend its FY2024 Form 10-K and Q1-Q3 2025 Form 10-Qs to restate the recognition of buildings as fixed assets versus right-of-use assets under ASC 842. The company explicitly states "The Prior Filings should no longer be relied upon because of errors identified in such financial statements," which is the hallmark of a financial restatement. This affects multiple periods and required a Form 12b-25 late filing notice, indicating material accounting corrections.
View raw filing on EDGAR →